These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28284178)

  • 1. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.
    Sezer A; Celik M; Yilmaz Bulbul B; Can N; Tastekin E; Ayturk S; Ustun F; Guldiken S; Sut N
    Bosn J Basic Med Sci; 2017 May; 17(2):144-151. PubMed ID: 28284178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis.
    Al Afif A; Williams BA; Rigby MH; Bullock MJ; Taylor SM; Trites J; Hart RD
    Thyroid; 2015 Sep; 25(9):1008-12. PubMed ID: 26161997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
    Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
    Park JS; Chang JW; Liu L; Jung SN; Koo BS
    Oral Oncol; 2017 Sep; 72():183-187. PubMed ID: 28222967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.
    Zheng X; Xia T; Lin L; Gao S; Lee Y; Yu Y; Wei S; Gao M
    World J Surg Oncol; 2012 Jun; 10():104. PubMed ID: 22681706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
    Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
    Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
    Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
    Beom Heo D; Piao Y; Hee Lee J; Ju SH; Yi HS; Su Kim M; Won HR; Won Chang J; Seok Koo B; Eun Kang Y
    Oral Oncol; 2022 Nov; 134():106115. PubMed ID: 36108524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
    Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.
    Park HS; Jung CK; Lee SH; Chae BJ; Lim DJ; Park WC; Song BJ; Kim JS; Jung SS; Bae JS
    Cancer Sci; 2012 Feb; 103(2):305-9. PubMed ID: 22118425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer.
    Tam AA; Özdemir D; Çuhacı N; Başer H; Aydın C; Yazgan AK; Ersoy R; Çakır B
    Endocrine; 2016 Sep; 53(3):774-83. PubMed ID: 27090526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
    Walts AE; Mirocha JM; Bose S
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evaluation of Clinicopathological Factors Effective in the Development of Central and Lateral Lymph Node Metastasis in Papillary Thyroid Cancer.
    Aydin Buyruk B; Kebapci N; Yorulmaz G; Buyruk A; Kebapci M
    J Natl Med Assoc; 2018 Aug; 110(4):384-390. PubMed ID: 30126565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.